Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon alpha-2b biobetter - HanAll Biopharma

Drug Profile

Interferon alpha-2b biobetter - HanAll Biopharma

Alternative Names: Hanferon; HL031 (oral interferon alpha-2b) - HanAll Biopharma; HL143 (subcutaneous interferon alpha-2b) - HanAll Biopharma; Modified interferon-alpha - HanAll Biopharma; Resis-IFN-alpha-2b

Latest Information Update: 11 Sep 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nautilus Biotech
  • Developer HanAll Biopharma; Nautilus Biotech
  • Class Antivirals; Biobetters; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cancer; Hepatitis C; Liver cancer

Most Recent Events

  • 11 Sep 2017 Discontinued - Phase-II for Hepatitis C in USA (SC)
  • 11 Sep 2017 Discontinued - Phase-II for liver cancer (Prevention of relapse) in USA (SC)
  • 17 Apr 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top